

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy ID4060

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
The company highlights that equality of treatment for children with cancer is a concern, and people with rarer forms of cancer report poorer experience of their treatment than people with more common forms of cancer. Also, intrinsic equality issues and challenges for medicines developed or licensed specifically in a paediatric population, for example, reduced sample sizes, single-arm designs, leading to uncertainties during NICE appraisals.
2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
The committee can consider the difficulties in evidence generation associated with the rarity of this condition, and that it is in a paediatric population.
3. Has any change to the draft scope been agreed to highlight potential equality issues?
No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No.

Approved by Associate Director (name): Jasdeep Hayre
2 September 2024

Date: